Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
MarketWatch on Twitter: "Teva Pharmaceutical named Kare Schultz as its new chief executive https://t.co/pyLR2vL5Ep https://t.co/pD8godrT5C" / Twitter
Teva Pharmaceuticals (@TevaUSA) / Twitter
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
Is Teva A Falling Drug Company Or A Great Value Proposition (NYSE:TEVA) | Seeking Alpha
Teva Stock Pressured From Antitrust Lawsuit Against Drug Makers | Barron's
Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva's Earnings and Outlook Miss Estimates. Currency Moves Are to Blame. | Barron's
Teva releases generic version of Mylan's EpiPen in limited doses in the U.S. - MarketWatch
Teva shares surge on corporate shake-up - MarketWatch
Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement | Barron's
Teva shares rise as company offers reassurance on former flagship drug Copaxone - MarketWatch
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
Teva: Avoid (NYSE:TEVA) | Seeking Alpha
Teva Stock Has Crumbled, and Chairman Sol Barer Is Buying Up Shares | Barron's
Drug maker Teva's U.S. unit indicted on price-fixing charges - MarketWatch
Teva to acquire Mexico's Rimsa for $2.3 billion - MarketWatch
Teva Appoints New Chief Executive After Months of Speculation - WSJ
Bulk of earnings pressure in the first half of 2023, says Citi's Scott Chronert
Drugmaker Teva Pharmaceuticals found guilty for contribution to opioid crisis - MarketWatch
Opinion: Multinationals learn the limits of being big - MarketWatch
I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study
